Alzheimer disease trials in Hungary

In Hungary 8 Also abroad 815

8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Where
Budapest, Budapest III, Debrecen, Dunaujvaros, Gyongyos, Győr, Kalocsa
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Budapest, Budapest XII, Gyongyos, Pécs
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Budapest, Budapest XII, Gyongyos, Miskolc, Pécs, Szeged
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Where
Budapest, Miskolc, Pécs
Age
55 years to 90 years
People
500 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Budapest, Budapest III, Debrecen, Dunaujvaros, Gyongyos, Győr, Kalocsa
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Where
Gyongyos, Pécs
Age
55 years to 90 years
People
300 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00
Phase 2Enrolling by invitation
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Where
Gyongyos, Pécs
Age
55 years to 91 years
People
210 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00
Phase 1Taking people
A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients
Where
Kistarcsa
Age
18 years and over
People
40
Run by
Mitochon Pharmaceuticals Inc.
See details and how to join2023-507195-43-00 · EU 2023-507195-43-00